Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
Hirotaka Watada, Akane Takami, Robert Spranger, Atsushi Amano, Yasuhiro Hashimoto, Elisabeth Niemoeller, Hirotaka Watada, Akane Takami, Robert Spranger, Atsushi Amano, Yasuhiro Hashimoto, Elisabeth Niemoeller
Abstract
Objective: To assess the efficacy and safety of a 1:1 fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naive Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs).
Research design and methods: In this phase 3, open-label, multicenter trial, 321 patients with HbA1c≥7.5 to ≤10.0% (58-86 mmol/mol) and fasting plasma glucose (FPG) ≤13.8 mmol/L (250 mg/dL) were randomized 1:1 to iGlarLixi or Lixi for 52 weeks. The primary end point was change in HbA1c at week 26.
Results: Change in HbA1c from baseline to week 26 was significantly greater with iGlarLixi (-1.58% [-17.3 mmol/mol]) than with Lixi (-0.51% [-5.6 mmol/mol]), confirming the superiority of iGlarLixi (least squares [LS] mean difference -1.07% [-11.7 mmol/mol], P < 0.0001). At week 26, significantly greater proportions of patients treated with iGlarLixi reached HbA1c <7% (53 mmol/mol) (65.2% vs. 19.4%; P < 0.0001), and FPG reductions were greater with iGlarLixi than Lixi (LS mean difference -2.29 mmol/L [-41.23 mg/dL], P < 0.0001). Incidence of documented symptomatic hypoglycemia (≤3.9 mmol/L [70 mg/dL]) was higher with iGlarLixi (13.0% vs. 2.5%) through week 26, with no severe hypoglycemic events in either group. Incidence of gastrointestinal events through week 52 was lower with iGlarLixi (36.0% vs. 50.0%), and rates of treatment-emergent adverse events were similar.
Conclusions: This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.
Trial registration: ClinicalTrials.gov NCT02749890.
© 2020 by the American Diabetes Association.
Figures
References
- Ministry of Health, Labour and Welfare Summary results of national health and nutrition survey [Internet], 2016. Available from . Accessed 8 August 2019
- Japan Diabetes Society Treatment. In Guideline for Treatment of Diabetes 2018–2019. Bunkodo, Tokyo, Japan Diabetes Society, 2018, p. 28–43
- American Diabetes Association 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl. 1):S90–S102
- Wang Z, Hedrington MS, Gogitidze Joy N, et al. . Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010;33:1555–1560
- McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965;25:1317–1324
- Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008;14:161–168
- Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–830
- Becker RHA, Stechl J, Steinstraesser A, Golor G, Pellissier F. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes Metab Res Rev 2015;31:610–618
- Hermanns N, Mahr M, Kulzer B, Skovlund SE, Haak T. Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study. Health Qual Life Outcomes 2010;8:113.
- Peyrot M, Rubin RR, Lauritzen T, et al. .; International DAWN Advisory Panel . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–2679
- Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411–3417
- Japan Diabetes Clinical Data Management Study Group Fundamental Statistics on Diabetes in Japan [Internet], 2017. Available from . Accessed 10 September 2019
- Odawara M, Matsuhisa M, Kuze T, et al. . Efficacy and safety of 12-month treatment with insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes: XSTAR study subanalysis (Abstract). J Jpn Diabetes Soc 2019;62(Suppl.):a92267
- Kobayashi M, Tsukube S, Ikeda Y, Shuto Y. Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 study, a post-marketing surveillance for Lantus. J Diabetes Mellitus 2014;4:273–289
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–742
- Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators . Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910–917
- Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461–2498
- Møller JB, Dalla Man C, Overgaard RV, et al. . Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab 2014;99:4273–4280
- Kuroe A, Fukushima M, Usami M, et al. . Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003;59:71–77
- Inoue K, Maeda N, Kashine S, et al. . Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 2011;10:109.
- Matsumoto S, Yamazaki M, Kadono M, et al. . Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J Clin Biochem Nutr 2013;53:68–72
- Yabe D, Kuroe A, Lee S, et al. . Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010;1:56–59
- Suzuki K, Akiyama M, Ishigaki K, et al. . Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nat Genet 2019;51:379–386
- Terauchi Y, Nakama T, Spranger R, et al. . Efficacy and safety of 26-week of insulin glargine/lixisenatide fixed ratio combination in Japanese patients with type 2 diabetes mellitus: comparison with insulin glargine (Abstract). J Jpn Diabetes Soc 2019;62(Suppl.):a92515
- Morita Y, Murayama H, Odawara M, Bauer M. Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetol Metab Syndr 2019;11:90.
- Aroda VR, Rosenstock J, Wysham C, et al. .; LixiLan-L Trial Investigators . Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care 2016;39:1972–1980
- Seino Y, Takami A, Boka G, Niemoeller E, Raccah D; PDY6797 Investigators . Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab 2014;16:739–747
- Inoue M, Lorenz M, Muto H, Wesch R, Hashimoto Y. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: a phase I randomized trial. Diabetes Obes Metab 2019;21:2001–2005
- Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group . Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559–569
- Odawara M, Kadowaki T, Naito Y. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study. J Diabetes Complications 2015;29:127–133
- Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408–416
- Rosenstock J, Aronson R, Grunberger G, et al. .; LixiLan-O Trial Investigators . Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care 2016;39:2026–2035
Source: PubMed